Coagulation abnormalities and thrombosis in patients with COVID-19

Bhatraju, 2020, Covid-19 in critically ill patients in the Seattle region—case series, N Engl J Med, 10.1056/NEJMoa2004500

Levi, 2018, How I treat disseminated intravascular coagulation, Blood, 131, 845, 10.1182/blood-2017-10-804096

Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, 18, 844, 10.1111/jth.14768

Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost

Thachil, 2020, ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J Thromb Haemost, 10.1111/jth.14810

Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032

Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3

Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0

Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res